Abstract 7810: Engineering macrophages as a novel therapeutic approach for high-risk neuroblastoma

Abstract Neuroblastoma (NB) accounts for 10% of pediatric cancer-related deaths. High-risk NB is frequently metastatic at diagnosis and has a poor 5-year survival rate (<50%) despite aggressive treatment. GD2, a disialoganglioside glycolipid that is expressed in nearly all NBs, has been validated as a promising immunotherapy target. Although GD2-CAR-T cells have been clinically evaluated, their efficacy has been limited by poor tumor infiltration and the immunosuppressive tumor microenvironment (TME), highlighting the need for alternative immune-based strategies. With inherent capacity of macrophages to infiltrate tumors, phagocytose cancer cells, and modulate TME, they represent a promising alternative strategy for immunotherapy in NB. In this study, we developed and evaluated GD2-CAR-macrophages (GD2-CAR-Ms) as a novel therapeutic approach for NB. GD2-specific CAR constructs were designed, validated, and introduced into multiple human and murine monocyte/macrophage cell lines via lentiviral transduction. Fluorescent microscopy and flow cytometry confirmed a significant enhancement in the phagocytosis of GD2-high NB cells by GD2-CAR-Ms containing Hu3F8 single-chain variable fragment (scFv). A strong positive correlation was observed between GD2 expression levels on the target cells and phagocytosis efficiency of GD2-CAR-Ms, indicating that the phagocytic activity of GD2-CAR-Ms is antigen-specific. Anti-tumor efficacy was further evaluated in vivo using an immunocompetent Mycn-expressing NB non-genetically engineered mouse model (MYCN-NGEMM). Mice treated with GD2-CAR-Ms exhibited significantly reduced tumor burden and prolonged survival compared to control groups. Notably, treatment of mice bearing GD2-high tumors resulted in markedly improved survival, including one complete remission among ten treated animals, underscoring the therapeutic potential of GD2-targeted macrophage therapy. Histological analysis showed increased deposition of connective tissues and decreased tumor cells density, suggesting TME remodeling. Furthermore, immunohistochemistry reveals increased immune cell infiltration, particularly of macrophages, neutrophils and T cells, indicating a favorable shift in the immune TME from “cold” to “hot” following GD2-CAR-M treatment. Additionally, inhibition of tumor growth was also observed in our zebrafish NB model after GD2-CAR-Ms treatment, further supporting their therapeutic potential. Together, our findings demonstrate that GD2-CAR-Ms exhibit potent antitumor activity and reshape the tumor immune microenvironment, supporting their translational potential as a therapeutic strategy for high-risk NB. Citation Format: Ke-En Tan, Kok Siong Yeo, Cheng Zhang, Caleb Baker, Shyang Hong Tan, Alexis M. Sosic, Yat-Yuen Lim, Choong-Yong Ung, Cristina Correia, Stephanie F. Polites, Yi Lin, William A. Weiss, Hu Li, Shizhen Zhu. Engineering macrophages as a novel therapeutic approach for high-risk neuroblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7810.